The history of mast cell activation dates back to the first documented case of utricaria pigmentosa in 1869 (Nettleship & Tay, 1869) . The first reported case of systemic mastocytosis (SM) was documented in France, in the 1930s, (S ezary et al, 1936) . SM is an infrequent disorder of mast cells activation and proliferation. It is characterized by a unique constellation of symptoms that originate from mast cell over-activity, resulting in the release of numerous cellular mediators, many of which are vasoactive. SM is notable for the overabundance and, often, activation of mast cells in extrahaematopoietic organs, which leads to a highly variable disease phenotype. Although previously thought to be closely related to the myeloproliferative neoplasms (MPNs), this disease subtype is no longer considered an MPN subgroup due to its unique clinical and pathological features and highly variable disease course (Arber et al, 2016) . The presence of activating somatic mutations in the KIT gene (CD117 receptor, usually the KIT Asp816Val D816V mutation) and aberrant immunophenotype associated with the expression of CD25 on clonal mast cells are found in most patients and represent critical biological markers that help to define the disease. Recent advances in SM for adult patients are promising and the treatment paradigm has changed significantly with the discovery and clinical testing of midostaurin. Although the treatment of paediatric SM patients is challenging and treatment modalities are available, they differ from the adult population and will not be covered in this article.
Diagnosis of SM

Clinical evaluation
The initial evaluation should focus on establishing the diagnosis and identification of the clonal origin of disease. At diagnosis, a complete medical history, including medication use, should be established. A comprehensive evaluation of symptoms should be taken (Fig 1) and triggers of mast cell activation symptoms should be assessed and documented (i.e., heat, friction, nonsteroidal anti-inflammatory drugs (NSAIDS), opioids, anaesthetics, contrast, vaccines, dextrans, anxiety, stress and insect bites]. Anaphylaxis history after exposure to foods, medications or other triggers, especially those needing the use of epinephrine, should be particularly noted.
Differential diagnosis of SM
Alternative cofounding diseases that may explain the persistence of symptoms should also be considered, including digestive (e.g., gluten enteropathy, coeliac disease, irritable bowel), endocrinological (e.g., pheochromocytoma, carcinoid syndrome), autoimmune (i.e., vasculitis) or neurological conditions (i.e., depression, fibromyalgia).
For those without evidence of a clonal cause of mast cell activity should be evaluated for mast cell activation syndrome (MCAS), a non-malignant condition associated with mast cell degranulation as well as for other conditions that may be associated with cell mediator release, such as carcinoid syndrome. The diagnosis of MCAS requires the presence of (i) typical clinical symptoms, (ii) Increase in serum total tryptase by at least 20% above baseline plus 2 ng/ml during or within 4 h after a symptomatic period, and (iii) Response of clinical symptoms to mast cell blocking agents, such as cromolyn (Valent et al, 2012) .
Diagnostic laboratory evaluation and testing
Measurement of an elevated serum tryptase is a finding typical of SM. In a review of 43 patients with SM, elevated serum tryptase was observed in the vast majority of patients (median 67 ng/ml) and there was a high correlation between grade of infiltration of the bone marrow (BM) by neoplastic mast cells and tryptase levels (r = 0Á8) . It is notable that, among that cohort, three patients with isolated BM mastocytosis had serum tryptase levels <20 ng/ml. Elevated tryptase >20 ng/ml and establishment of clonal mast cells in tissues is central to the diagnosis of SM as identified by the World Health Organization (WHO) diagnostic criteria for SM (Vardiman et al, 2009) . Figure 2 illustrates a suggested outline for the work-up, diagnosis and initial treatment of SM patients. For those who have undergone a previous work-up, there is a role for re-evaluating involved tissues for mast cell testing if there is clinical suspicion, as there may be focal involvement of certain tissues (Arber et al, 2016) . Previous biopsies, most notably, skin, colon or liver biopsies, should be re-reviewed for the presence of mast cells if symptoms or end organ effects are present in these systems. Peripheral blood should be assessed for the presence of eosinophilia or other white blood abnormalities that may suggest a clonal aetiology.
KIT mutational analysis
Greater than 90% of patients harbour a gain-of-function KIT mutation and more than 80% will be found to have the KIT D816V mutation (Wang et al, 2013; Chatterjee et al, 2015) . Peripheral blood KIT testing can be pursued to help establish the clonally of the mast cell aggregates. Additionally, further staining to establish the expression of CD2 and/or CD25 should be considered. BM or suspected involved organ biopsy (such as liver or colon) should be obtained if there is suspicion for extensive involvement outside the skin. The degree of KIT D816V mutational status in SM can be highly variable given the differing degrees of mast cell infiltration in affected organs. In one review, the rate of KIT mutation in mononuclear cells varied between skin, BM (combined frequency of mutational sensitivity of 95%) and blood (81%) and may be observed at a frequency as low as low as 0Á03% mutation-positive cells (Kristensen et al, 2011) . Based on the patients' history, if there is suspicion of a clonal cause of symptoms, or refractory symptoms are present, KIT D816V should be evaluated for possible clonality. Individuals who do not meet the criteria for diagnosis may be monitored and/or rebiopsied for suspected tissue involvement with staining for CD117 + cells. The types of mast cell clonality are broad, ranging from skin-only disease to widely-spread organ involvement (Table I) .
Classification of mastocytosis
Cutaneous mastocytosis
Cutaneous mastocytosis can be diagnosed by skin only manifestations that are diffuse with negative end-organ biopsies. Cutaneous mastocytosis is the most common presentation of mast cell disease, representing 90% of cases. 
Systemic mastocytosis
Once the disease can be identified in organs other than the skin or there are symptoms suggestive of end-organ involvement, a diagnosis of other types of SM can be made. Outside of skin involvement, BM involvement of mast cells is most common.
Indolent SM. Indolent SM is the most common form noncutaneous of SM and can often encompass a range of symptoms related to gastrointestinal (GI), skin, and cognitive effects (Fig 1) . It is characterized, however, by the lack of BM or end organ involvement, which would compromise organ functioning. Smouldering SM is a more rare subtype of disease with uncertain clinical course where there is evidence of organ involvement, but no negative end organ effects . B-findings, or features associated with physical abnormalities such as splenomegaly, hepatomegaly or lymphadenopathy, or myeloproliferation or dysplasia on BM biopsy are usually only present in those Systemic mastocytosis with an associated haematological neoplasm (SM-AHN). SM-AHN tends to be observed in an older population of patients and carries a more aggressive clinical course. Types of associated haematological malignancies included chronic myelomonocytic leukaemia (CMML), myelodysplastic syndrome (MDS), B-cell lymphoma/leukaemia/plasma cell neoplasms, myeloproliferative neoplasms and acute myeloid leukaemia (AML) (Wang et al, 2013) .
Mast cell leukaemia (MCL)
. MCL carries the highest mortality and is defined by the presence of at least 20% neoplastic mast cells in marrow and 10% in blood and is generally considered a subtype of acute leukaemia. For individuals who do not carry at least 10% of peripheral blood positive cells, the tumour is called aleukaemic MCL.
Genetic mutations and prognosis
Much of our diagnosis and treatment choices in SM revolve around the subtype of SM as well as the results of genetic testing. The prognosis of SM patients varies from indolent limited involvement disease to severe end organ damage and death, a result of highly diverse disease phenotypes. In routine practice, the WHO classification of SM has also served as the gold standard prognostic system. A large patient registry recently published the results of their findings as well as a modified prognostic scoring system . In this analysis, patients with advanced SM were found to be older, to have higher serum tryptase and alkaline phosphatase levels, higher white blood cell counts, lower haemoglobin concentration and platelet counts, and more frequently presented with organomegaly (i.e., hepatomegaly, splenomegaly or lymphadenopathy). Moreover, the male/female ratio was higher in advanced mastocytosis. By multivariate analysis, a prognostic scoring system was developed that utilizes the WHO classification . Individuals with low risk disease (i.e., cutaneous SM, mastocytosis in the skin, indolent SM, smouldering SM) without additional risk factors were designated into the low risk group with the median overall survival (OS) not reached (median observation period was 3Á5 years, however, a plateau in the Kaplan Meyer curve was observed, suggesting a 70% or greater overall probability of survival at 24 months). Those with non-advanced disease and presence of one or more risk factors, including age >70 years, platelets <80 9 10 9 /l or alkaline phosphatase ≥240 u/l, were placed in the intermediate risk category with a median OS of 13Á5 years. Those with advanced disease (regardless of additional risk factors) were designated as high risk, with a median survival of 3Á5 years . The expression of KIT, a transmembrane tyrosine kinase receptor for stem cell factor, can be expressed on melanocytes and mast cells. Mutated KIT, typically harbouring the Asp816Val (KIT D816V) in the catalytic domain of KIT, stimulates mast cell proliferation and immortality (Carter et al, 2014) . The availability of next generation sequencing has led to the identification of the KIT D816V mutation in over 93% of cases of SM. Other mutations, although rare, can be present including exon 17 D816Y, 815-817 indels and exon 11 mutations.
Genetic analysis beyond KIT offers alternative methods beyond WHO diagnosis to estimate prognosis and tailor treatment for SM patients. Tefferi and colleagues has recently published the results of 148 non-KIT mutated patients . The most commonly identified additional mutations included TET2 (29%), ASXL1 (17%) and CBL (11%), with the highest mutational frequency in SM with associated haematological neoplasm compared to other disease subtypes (P < 0Á0001). Alternative analysis confirmed that individuals with SM often carried secondary mutations commonly seen in myeloid neoplasms, including JAK2 V617F, TP53, SRSF2, ASXL1, RUNX1 or TET2 (Naumann et al, 2016) . Using this data, developed a clinical-molecular prognostic model (Table II) . This and similar findings have also led to the recommendation that all patients who present with advanced SM should undergo routine molecular and cytogenetic testing in addition to traditional baseline pathological and imaging studies, as these patients carry high risk of progression and transformation (Naumann et al, 2016) . This recommendation is particularly relevant to patients with SM-AHN, who often have genetic drivers consistent with both KIT D816V and a second mutation which fuels independent AHN evolution (Naumann et al, 2016) . Additional mutations between Fip1-like-1 (FIP1L1) and platelet-derived growth factor receptor alpha (PDGFRA) create a tyrosine kinase that is responsive to imatinib and can be associated with peripheral and BM eosinophilia (Pardanani et al, 2003) A deletion noted at locus 4q12 of CHIC2 can be identified as a proxy of this fusion gene.
Treatment of indolent SM
The backbone of treatment for cutaneous, indolent and smouldering SM is symptom management and continued monitoring (Table III) (Tefferi & Pardanani, 2004; Akin & Gotlib, 2017) A suggested algorithm for the initial approach to diagnosis and management of SM is outlined in Fig 2. This approach emphasizes the need for re-review of a patient's symptomatology over time as well as incorporating the utilization of newer agents compared to previously published algorithms (Theoharides et al, 2015) .
Patients with these less aggressive forms of SM should be monitored on a regular basis for signs of progression, which can be heterogeneous. Increasing frequency or severity of disease-related symptomatology, including GI, skin, pulmonary or neurological symptoms, should be monitored. Patients should also be monitored for the development of B or C findings (Table I) , such as abnormal blood counts and end organ effects that may suggest disease transformation into more a aggressive form. The role of monitoring KIT D816V mutation allele burden in patients has not yet been established, although allele burden can predict survival (P < 0Á01) and correlate with response to therapy (P < 0Á05) (Hoermann et al, 2014) . Patients with significantly increasing serum tryptase levels (slope ≥0Á15) after 48 months of follow-up demonstrated a significantly greater frequency of cases with progression to smouldering and aggressive SM (P = 0Á03) and a shorter progression-free survival (P = 0Á03) (Matito et al, 2013) . Alternative long-term studies of indolent SM have demonstrated that a combination of serum beta2-microglobulin (P = 0Á003) with the presence of KIT mutations in mast cells plus myeloid and lymphoid haematopoietic lineages (P = 0Á02) was predictive of disease progression (Escribano et al, 2009) .
Reducing disease-related symptoms represents the mainstay of treatment for less aggressive forms of SM due to the excellent prognosis among most patients with these disease subtypes. First and foremost, all SM patients and their caregivers should be aware of the potential triggers of an SM symptom episode and find ways to avoid excessive mast cell activation in situations that may have caused activation in the past. The origin of symptoms in SM result from overactivation of mast cells, resulting in the release of histamine, proteoglycans (including heparin), tryptase, acid hydrolases, leukotrienes, prostaglandins, platelet activating factor, interleukins and tumour necrosis factor. The triggers of mast cell degranulation are complex, and can include emotional stress, physical stimuli (such as trauma), infections, allergic symptoms (i.e., bee stings, asthma exacerbations) and medications. Drugs such as alcohol, aspirin, NSAIDS, opioids, anticholinergics and radioactive dyes, can precipitate mast cell degranulation and should be avoided. All patients with proven clonal SM of any subtype should also be provided with an epinephrine pen to use in case of anaphylaxis and instructed on when to present to the emergency department for evaluation. Medical alert bracelets can be considered depending on the severity of the disease.
Treatment of cutaneous SM
The mainstay of management in cutaneous SM is localized treatment. Topical steroids are useful when skin lesion size and distribution are limited. Rarely, intralesional injections of small amounts of may help to resolve skin lesions that are particularly bothersome or if daily administration of steroids is not feasible. Oral psoralen, possibly combined with ultra violet (PUVA) treatment can lead to improved cosmetic and symptomatology and is generally reserved for cases of cutaneous SM unresponsive to oral steroids (Mackey et al, 1996) .
Treatment of extracutaneous SM
Systemic symptoms may be GI, pulmonary, bone, skin or cognitive in origin (Fig 1) and are present in the majority of patients with extracutaneous disease. Histamine-2 (H1) antagonists can be used to treat skin symptoms that include erythema, flushing, pruritus and bullae . H2 antagonists can be useful for GI-related symptoms, including dyspepsia. Hydroxyzine or doxepin can also be Table III . Pharmacological therapies for symptom control (Tefferi & Pardanani, 2004; Akin & Gotlib, 2017 Cytokine/immunomodulatory drug IFN-a, starting dose, 1-3 million units (mu) SC 3 9 per week; target dose, 3-5 mu SC 3-5 9 per week Third line Purine nucleoside analogue 2-CdA, 5 mg/m 2 IV 9 5 days every 4-8 weeks 2-CdA: 2-chlorodeoxyadenosine; BID: twice daily; IFN-a: interferon a; IV: intravenously; q: every; QID: 4 times per day; SC: subcutanelously; UVA: ultra-violet A.
useful for pruritus. Leukotriene antagonists are most useful as second line therapy for pruritus and, along with cromolyn, can help prevent mast cell degranulation. Cromolyn is effective in reducing GI symptoms (particularly diarrhoea, abdominal pain and nausea) as well as with reports of decreased bone pain and headaches (Miner, 1991) . NSAIDS can be helpful to ease bony pain and bothersome skin symptoms. Aspirin may precipitate mast cell activation, and thus should be used in the setting of symptoms refractory to H1 or H2 blockade, with patients closely monitored during treatment initiation. The use of systemic steroids is typically limited to specific situations in which mast cell flares must be acutely managed or in the setting of end-organ issues. Long-term use is limited by the lack of long-term efficacy and secondary effects, such as low bone density, which may be compounded in SM patients due to a pre-existing susceptibility for osteoporosis development (Rossini et al, 2011) . Omalizumab, a monoclonal antibody that binds IgE, should be considered for use in select patients with severe symptoms that have proven unresponsive to leukotriene antagonists or cromolyn Gonzalez-de-Olano et al, 2016) . Individuals with low bone density should be given calcium and vitamin D and be considered for bisphosphonate treatment as per standard guidelines. The optimal duration of therapy is unknown, but a 5-year course of treatment could be considered. Consideration should also be given to the psychological well being of SM patients, who are at particularly high risk of depression. Selective serotonin reuptake inhibitors can be considered for treatment in this setting.
Mastocytosis in pregnancy
Mastocytosis in pregnancy is a particular challenge, as approximately 30% of women will note the worsening of symptoms during pregnancy, a change that is thought to be precipitated by increased oestrogen levels (Worobec et al, 2000) . The active components of mast cell degranulation are critical as well as problematic in pregnancy, as they may contribute and modulate myometrical contractility and post-partum uterine tissue remodeling (Woidacki et al, 2014) . During the course of the pregnancy, symptoms can be managed with the use of second-generation H1 blockers, such as loratidine or desloratadine (Schwarz et al, 2008) . In general, all patients are recommended to have antihistamines and corticosteroids available at the time of birth. For those with a history of anaphylaxis, epinephrine should be kept at the bedside.
Treatment of rapidly progressive systemic SM, aggressive SM and MCL
Newly available and late phase trials for investigational agents with activity in progressive SM, aggressive SM and MCL has Midostaurin is a tyrosine kinase inhibitor that is effective against KIT D816V with an overall response rate of 60% in advanced SM patients . Midostaurin is tolerable, with the most frequent adverse events being lowgrade nausea, vomiting and diarrhoea. However, despite initial disease control, continuous complete remission is not seen in in all patients. Efforts to determine which patients will lose response have indicated that, at 6 months following midostaurin initiation, factors including reduction of KIT D816V expressed allele burden of less than <25% (P = 0Á0004), serum tryptase reduction <50% (P = 0Á03) and alkaline phosphatase reduction <50% (P = 0Á04) were associated with reduced OS. Serial next generation sequencing also revealed the acquisition of RUNX1, K/NRAS, IDH2 or NPM1 in a cohort of patients who had progressive disease and had passed away (Jawhar et al, 2016a) . The U.S. Food and Drug Administration approved midostaurin for the treatment of aggressive SM on 28 April 2017 (U.S. Food and Drug Administration, 2017). Prior to this, imatinib was approved in 2006 for use in adult patients with aggressive SM without the KIT D816V mutation or with unknown KIT mutational status. Along with this approval, midostaurin is approved for use in patients with AML who are FLT3 mutation-positive (FLT3 + ), in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
Although midostaurin represents the most potent and effective agent available for SM patients to date, other medications are under investigation that may also help to modify disease activity. Studies are currently ongoing in regards to alternative KIT inhibitors, namely, the highly selective KIT D816V inhibitor, BLU-285, has significant activity against this mutation with in vitro and in vivo testing, even in cases which are resistant to midostaurin (Jawhar et al, 2016b) . In the results of a phase I clinical trial of BLU-285 in advanced mastocytosis, BLU-285 was well tolerated and demonstrated objective decreases in mast cell burden and reduction in mast-cell-related organ damage. BLU-285 was well tolerated among this small cohort (N = 6) with confirmed D816V mutation in blood and BM. All patients had at least one co-occurring genetic modifier mutation (such as TET2, DNMT3A or GATA1) and mast cell-related organ damage, as evidenced by at least one C-finding. Among those treated with BLU-285, the drug appeared very well tolerated with no grade 4 or above events and most adverse events being grade 1. Notable grade 2 events included fatigue, dizziness, headache, rash, shingles, anaemia, elevated gamma-glutamyltransferase and thrombocytopenia. The duration of therapy ranged from 2-5 cycles and treatment was on-going for many patients. Regardless of dose level, patients experienced improvements in disease-related symptoms, including urticaria pigmentosa, decrease in steroid use and weight gain. Albumin increased and many patients experienced decreases in malabsorption. Peripheral blood and BM KIT D816V DNA levels, splenomegaly, peripheral blood tryptase and BM biopsy mast cell frequency all decreased.
Masitinib is a new agent that recently underwent randomized placebo-controlled phase III testing in patients with indolent or smouldering SM (Lortholary et al, 2017) . Masitinib inhibits KIT, FLN and LYN kinases, which are instrumental in mast cell pathogenesis. In this trial, individuals with indolent or smouldering SM (N = 135) were randomized to receive masitinib (n = 71) or placebo (n = 64) (Lortholary et al, 2017) . The response rate (as measured by symptoms including pruritus, flushes, depression and asthenia) among the Masitinib-treated patients was 18Á7% (compared to 7Á4% placebo). Few severe adverse events occurred at a higher frequency among than masitinib compared to placebo (>4% difference between groups), consisting of diarrhoea (11% vs. 2%), rash (6% vs. 0%) and asthenia (6% vs. 2%). No life threatening toxicities occurred.
In individuals expressing the FIP1L1/PDGFRA+ (e.g., eosinophilia with accompanying rearrangement of PDGFRA in cells of myeloid lineage) or in individuals who harbour KIT mutations outside of exon 17, imatinib and other tyrosine kinase inhibitors (TKIs) can be effective (Mital et al, 2011; Ustun et al, 2011) . In these imatinib-resistent cases, interferon-alpha induced mast cells frequency in the BM as well as total serum tryptase (Yoshida et al, 2009) . Imatinib has also been found to be effective in two individuals with familial-associated mastocytosis both in vitro and in vivo (Zhang et al, 2006) . In this family, a novel exon 9 mutation was identified in the KIT coding region with an A>T mutation at nucleotide 1547 [K509I] .
Dasatinib also blocks the tyrosine kinase activity of KIT D816V and has shown activity in aggressive forms of SM. Dasatinib is a orally available SRC/ABL inhibitor that has also demonstrated activity to BCR-ABL isoforms resistant to in vitro imatinib. Initial evaluation of dasatinib in in vitro and cell-based kinase studies demonstrated significant inhibitory effects to both wild-type KIT and the D816V mutation (Shah et al, 2006) . In a phase II trial, Dasatinib was administered orally at 70 mg twice daily over a median of three months (Verstovsek et al, 2006) . Overall response rate to dasatinib was 37%. Although 29% of patients experienced symptomatic improvement, no significant response in the frequency of BM mast cells or blood tryptase levels were observed.
The role of cytoreductive agents is not well established, but these agents have been used successfully for the treatment of SM patients. Interferon is particularly helpful in the setting of pregnant patients who require disease control outside of modification of mast cell activity. In a phase II trial of interferon alpha (1-5 million units/m 2 /day subcutaneously with progressive dose intensification) among 20 patients, seven partial and six minor responses were experienced over 6 months (Casassus et al, 2002) . Of those with BM infiltration (n = 12/20), this remained unchanged. However, an unexpectedly high rate of clinical depression was observed (35%). Additionally, two patients died shortly after treatment initiation due to cardiovascular incidence and sepsis. In a retrospective review among patients treated at the Mayo Clinic, overall response rates for interferon with or without steroids (n = 40) and hydroxycarbamide (n = 26) were 53% and 19%, respectively (Lim et al, 2009) . Major response was observed in 18% of interferon-treated and 0% of hydroxycarbamide treated patients. Cladribine [chlorodeoxyadenosine or 2-CdA] given at a dose of 0Á14 mg/kg given over 1-5 days and repeated at 4-12 weeks for an average of 3Á7 cycles) was demonstrated to have long-term success among a cohort of 68 indolent and advanced SM patients (Barete et al, 2015) . Overall response rate among this cohort was 72% with a major response rate of 47% and an average response duration of 2Á47 years (aggressive SM) to 3Á71 years (indolent SM). Significant improvement was noted for most tested markers of mast cell mediator release [such as tryptase (P = 0Á01)] and mast cell infiltration-related symptoms [including urticaria pigmentosa and organomegaly (P < 0Á02)]. Grade 3/4 toxicities included lymphopenia (82%), neutropenia (47%) and opportunistic infections (13%).
Numerous drugs are still undergoing early clinical trial investigations. The role of mammalian target of rapamycin (mTOR) and phosphatidyl inositol 3 kinase (PI3K) inhibitors are yet undergoing investigation as they target critical downstream KIT signalling. CD30 has been identified as being overexpressed in neoplastic SM cells. In a recent case series of 4 patients treated with an anti-CD30 antibody drug conjugate, brentuximab vedotin, patients demonstrated sustainable treatment response and good drug tolerability (Borate et al, 2016) . Multi-kinase inhibition has also become a frequent target for new drug development and testing, partly due to the success of these drugs in controlling a murine models of allergy syndromes. Sunitinib has been used in one human case with life-threatening MCAS multi-drug refractory SM and was able to achieve prompt complete remission without evidence of toxicity (Afrin et al, 2015) The oral JAK1/JAK3 inhibitor, tofacitinib, which is approved for use in the United States for treatment of rheumatoid arthritis, was also found to quickly induce substantial symptomatic improvement . Recent results of a study to evaluate the effects of the multi-kinase inhibitor DCC-2618 on proliferation indicated that this may be a promising agent to reduce proliferation and survival of primary neoplastic mast cells in The role of stem cell transplantation (SCT) in SM SCT should be considered in patients with aggressive disease who are young and otherwise healthy, as this is the only option for a sustained response. In the largest published cohort of SM patients undergoing SCT to date, of 57 patients in Europe and the United States, the success of alloSCT was found to be highly variable based on SM subtype and curative for only a minority of patients (Ustun et al, 2014 b) . SM-AHN patients with secondary malignancies, including AML, MDS, MPNs or MDS/MPN overlap syndromes, demonstrated a greater than 70% survival by 3 years. The survival of individuals undergoing SCT for advanced SM and MCL at 3 years was 43% and 17%, respectively. The frequency of progression-free survival was low for all participants (57% at 1 year), but it was notable that, if the persistence of mast cells were observed often no progression was seen. Treatment-related mortality was generally similar to other haematological malignancies (20% at 12 months post-transplant) (Ustun et al, 2014 b) . Based on this and smaller analyses, consensus guidelines have been recently been published which outline suggested treatment recommendations as to when to consider transplantation in SM patients (Ustun et al, 2016 c) .
Prior to SCT, combinational therapy should be attempted to bring the patient to best response. Either cladrabine or midostaurin should be considered as interim therapy for individuals with slow progression or who require bridge to transplantation. In a phase II trial using midostaurin in MCL patients without allogeneic haematopoietic stem cell transplantation, midostaurin demonstrated a median OS of 9Á4 months (95% confidence interval, 7Á5 to not estimated) . Alternative treatment options included combining high-dose cytosine arabinoside and a nucleoside, such as fludarabine. In the interim, systemic corticosteroids can be effective to aid with improvement in ascites, malabsorption, or severe skin disease, although long-term use is not recommended. The use of interferon-alpha is not recommended prior to SCT given the possible increased frequency of acute graft-versus-host disease (GVHD) (Morton et al, 1998) .
SM-AHM is one of the most frequent causes for SMrelated transplant referral, notably due to the potentially good outcomes and challenges with alternative treatment choices. It has been recognized that KIT D816V is associated with poor outcomes in AML and the additional finding of clonal mast cells is associated with poor outcomes for other haematological malignancies, although it is not recommended that a patient with a low risk AHM undergo transplantation if accompanying occult SM is found (Ustun & Marcucci, 2015; Ustun et al, 2016) . For patients with chronic myeloid leukaemia and aggressive SM, the decision for transplant should be based on the presence of disease-related organ dysfunction or rapid clinical progression. Investigations into the role of molecular markers in this setting are ongoing. Transplantation should be considered at the time of best treatment response, particularly for young and otherwise healthy patients with good donor options (Ustun et al, 2016) .
Despite these recommendations, no prospective trials have been completed that address key questions regarding transplantation, including optimal timing, debulking strategy, conditioning, or GVHD prophylaxis (Ustun et al, 2016) . No studies or clear recommendations exist with regard to myeloablative conditioning over nonmyeloablative/reducedintensity conditioning in patients with advanced SM. However, with the relatively high relapse rate post-transplant, previous cohort analysis suggest that myeloablative conditioning may lead to improved relapse-free survival, particularly in young patients with good pre-transplant health status (Ustun et al, 2014) . Outcomes among human leucocyte antigen (HLA)-matched sibling transplantations and unrelated HLAmatched donor transplantations were similar, and little data is available with regard to cord blood and haploidentical transplants (Ustun et al, 2016) . Although no significant differences in GVHD prophylaxis were observed in the largest retrospective cohort to date, there is some thought that the mTOR inhibitor, sirolimus, may be useful as it has also been demonstrated to inhibit the in vitro proliferation and survival of KIT D816V-mutated mast cells (Gabillot-Carr e et al, 2006) . It is considered standard practice to have readily available epinephrine and concurrent use of prophylactic use of H1 and H2 antihistamines and, possibly, steroids during administration of the conditioning regimen (Ustun et al, 2016) . Although little information is available for relapsed SM, limited data suggests that midostaurin administration appears safe following transplant (Stone et al, 2015) .
Conclusions
The unique clinical profile of SM patients and expansion in our understanding of the molecular underpinnings of disease and pharmacological advancements provides both challenge and opportunity for the SM clinician. With the recent development of SM patient registries, we can foreseeably improve the identification and monitoring of SM patients throughout their disease course Lee et al, 2016) . The role of next generation sequencing to identify patients who might carry additional genetic markers that may predispose them to a worse prognosis is still very new and has yet to be widely utilized. Certainly, the treatment of advanced SM represents an unmet need. The role of new therapies that may offer durable response has still yet to be defined. Importantly, the treatment of SM patients, particularly aggressive SM, needs to be undertaken at a tertiary care facility that may has access to clinical trials. The next decade is likely to bring significant diagnostic and treatment advancements for SM patients.
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